Добірка наукової літератури з теми "Prostaglandins Antagonists"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Prostaglandins Antagonists".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Prostaglandins Antagonists"
Vanner, S., M. M. Jiang, and A. Surprenant. "Mucosal stimulation evokes vasodilation in submucosal arterioles by neuronal and nonneuronal mechanisms." American Journal of Physiology-Gastrointestinal and Liver Physiology 264, no. 2 (February 1, 1993): G202—G212. http://dx.doi.org/10.1152/ajpgi.1993.264.2.g202.
Повний текст джерелаBanks, R. O., and E. D. Jacobson. "Renal vasodilation with ureteral occlusion and prostaglandins: attenuation by histamine H1 antagonists." American Journal of Physiology-Renal Physiology 249, no. 6 (December 1, 1985): F851—F857. http://dx.doi.org/10.1152/ajprenal.1985.249.6.f851.
Повний текст джерелаLonardoni, Maria Valdrinez Campana, Momtchillo Russo, and Sonia Jancar. "Essential Role of Platelet-Activating Factor in Control of Leishmania (Leishmania)amazonensis Infection." Infection and Immunity 68, no. 11 (November 1, 2000): 6355–61. http://dx.doi.org/10.1128/iai.68.11.6355-6361.2000.
Повний текст джерелаYe, Yao, Peng Lin, Junyan Zhu, Udo Jeschke, and Viktoria von Schönfeldt. "Multiple Roles of Prostaglandin E2 Receptors in Female Reproduction." Endocrines 1, no. 1 (May 6, 2020): 22–34. http://dx.doi.org/10.3390/endocrines1010003.
Повний текст джерелаRibeiro-Junior, Jerônimo Aparecido, Marcelo Franchin, Miriam Elias Cavallini, Carina Denny, Severino Matias de Alencar, Masaharu Ikegaki, and Pedro Luiz Rosalen. "Gastroprotective Effect of Geopropolis fromMelipona scutellarisIs Dependent on Production of Nitric Oxide and Prostaglandin." Evidence-Based Complementary and Alternative Medicine 2015 (2015): 1–5. http://dx.doi.org/10.1155/2015/459846.
Повний текст джерелаHealy, DL. "Progesterone receptor antagonists and prostaglandins in human fertility regulation: a clinical review." Reproduction, Fertility and Development 2, no. 5 (1990): 477. http://dx.doi.org/10.1071/rd9900477.
Повний текст джерелаHealy, David L. "Prostaglandins and Progesterone Receptor Antagonists in Human Fertility Regulation." Australian and New Zealand Journal of Obstetrics and Gynaecology 34, no. 3 (June 1994): 357–60. http://dx.doi.org/10.1111/j.1479-828x.1994.tb01089.x.
Повний текст джерелаKnauss, T., and H. E. Abboud. "Effect of serotonin on prostaglandin synthesis in rat cultured mesangial cells." American Journal of Physiology-Renal Physiology 251, no. 5 (November 1, 1986): F844—F850. http://dx.doi.org/10.1152/ajprenal.1986.251.5.f844.
Повний текст джерелаGulla, Surendra, Dakshayani Lomada, Anusha Lade, Reddanna Pallu, and Madhava C. Reddy. "Role of Prostaglandins in Multiple Sclerosis." Current Pharmaceutical Design 26, no. 7 (March 25, 2020): 730–42. http://dx.doi.org/10.2174/1381612826666200107141328.
Повний текст джерелаFattahi, Mohammad Javad, and Abbas Mirshafiey. "Prostaglandins and Rheumatoid Arthritis." Arthritis 2012 (November 7, 2012): 1–7. http://dx.doi.org/10.1155/2012/239310.
Повний текст джерелаДисертації з теми "Prostaglandins Antagonists"
Ratzlaff, Viviane. "Padronização e validação de um novo modelo de febre induzida pela injeção intratecal de prostaglandina e2 em ratos jovens." Universidade Federal de Santa Maria, 2006. http://repositorio.ufsm.br/handle/1/11148.
Повний текст джерелаA febre, apesar de fazer parte da resposta de defesa do hospedeiro à infecção ou inflamação, está associada com desconforto e ansiedade, além de representar um risco iminente de convulsões febris em crianças. Por isso, terapia antipirética é rotineiramente prescrita a pacientes febris. Os modelos animais de febre empregando a injeção sistêmica de lipopolissacarídeo (LPS) e fermento de padeiro, descritos na literatura, são úteis para a triagem de novos antipiréticos, mas não fornecem informações a respeito do mecanismo de ação desses compostos. Diante disso, o presente estudo objetivou padronizar e validar um modelo de indução de febre por prostaglandina (PG) E2, o mediador final da resposta febril no sistema nervoso central, em ratos machos jovens da raça Wistar (25-30 dias). Neste protocolo, a PGE2 foi injetada pela via intratecal (i.t.), não necessitando a implantação de cânula. A temperatura retal (TR) foi registrada a cada trinta minutos durante três horas após a injeção da PGE2 (08:00-11:00 h). A injeção i.t. de PGE2 10 ηg em 100 μL/animal induziu febre nos animais, a qual foi prevenida pela administração de antagonistas dos receptores EP1 e EP3, mas não por antagonista do receptor EP4. Além disso, os antipiréticos clássicos dipirona e paracetamol, em doses que não tiveram efeito per se na TR dos animais, não reverteram a febre induzida por PGE2 i.t. Este modelo parece útil para investigar se a ação dos antipiréticos ocorre antes ou depois da ligação da PGE2 em seus receptores EP. Além disso, este protocolo é vantajoso do ponto de vista técnico, ético e econômico em relação aos outros protocolos de indução de febre por PGE2 descritos na literatura, porque a trepanação para implantação de cânula não é necessária, reduzindo a resposta inflamatória, o sofrimento dos animais e os custos experimentais.
Perrin, Véronique. "Synthèse et caractérisation pharmacologique de nouveaux antagonistes potentiels des récepteurs du thromboxane A2." Lyon 1, 1996. http://www.theses.fr/1996LYO10314.
Повний текст джерелаEckert, David. "The Prostaglandin E2 Receptor 1 (EP1) Antagonizes AngII in the Collecting Duct." Thesis, Université d'Ottawa / University of Ottawa, 2017. http://hdl.handle.net/10393/36196.
Повний текст джерелаFukuda, Miyuki. "Exacerbation of Intracranial Aneurysm and Aortic Dissection in Hypertensive Rat Treated With the Prostaglandin F-Receptor Antagonist AS604872." Kyoto University, 2016. http://hdl.handle.net/2433/204574.
Повний текст джерелаRiveron, Véronique. "Synthèse et étude de nouveaux antagonistes potentiels du thromboxane A2 et de la prostaglandine H2 faisant intervenir un squelette 2-azanorbornane." Lyon 1, 1993. http://www.theses.fr/1993LYO10293.
Повний текст джерелаTraversa, Christel. "Synthèse et étude de nouveaux antagonistes potentiels du thromboxane A2 à partir d'aza-7-norbornadiènes." Lyon 1, 1994. http://www.theses.fr/1994LYO10305.
Повний текст джерелаÁVILA, Roberta Marques Dias de. "Planejamento, síntese e avaliação farmacológica de derivados indano-hidrazônicos, candidatos a protótipos de fármacos anti-inflamatórios." Universidade Federal de Alfenas, 2010. https://bdtd.unifal-mg.edu.br:8443/handle/tede/375.
Повний текст джерелаNSAIDs are an important class of drugs with therapeutic applications that have already been used by more than a century. The evolution of treatment of chronic inflammatory diseases such as rheumatoid arthritis and osteoarthritis has its mark from indomethacin, one of the representatives of traditional NSAIDS for later rise and more recently the disuse of inhibitors with high selectivity for PGHS-2. The effort to discover safer and more effective drug remains a challenge and the search for new anti-inflammatory agents and analgesics have led to the planning and the discovery of numerous active acyl and aryl-hydrazones. And there are several active ligands able to act on the arachidonic acid cascade results identified subunits acyl and aryl-hydrazones as important pharmacophore for inhibition of the inflammatory process. Despite the rationalization of the results and studies of structure-activity relationship in the biological profile of the subunits acyl and aryl-hydrazones, we could not yet identify because of the mechanism of action of such groups. Safrole, which is a allylbenzene wide distribution in the plant kingdom, has interesting physical and chemical properties for use as a starting product for the synthesis of new molecules designed and is widely used in research projects at the Laboratory of Phytochemistry and Medicinal Chemistry . This paper describes the design and synthesis of new indane-hydrazone candidates prototype antiinflammatory drugs. The synthetic route was planned in three stages, using reagents of low cost and relatively simple methods. The compounds obtained were planned and evaluated in order to observe the anti-inflammatory effect from preliminary tests (number of writhing induced by acetic acid) held in the Biomedical Institute of Universidade Federal Fluminense - UFF. It was possible to identify all congeners showed that inhibition was the most active of the series of synthesized molecules was derived (1c) and (1e) with 51.0% and 48.6% inhibition of writhing induced by acetic acid.
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES
Günther, Jan [Verfasser]. "Prostaglandin-EP3-Rezeptor-vermittelte Hemmung der Monoamin-Freisetzung in Nagergewebe : Beweis mit dem kompetitiven Antagonisten L 826266 / Jan Günther." Bonn : Universitäts- und Landesbibliothek Bonn, 2015. http://d-nb.info/1080592016/34.
Повний текст джерелаWisehart, Veronica. "An antagonist of the prostaglandin F2α receptor (FP)- Gaq-dependent respone, biases FP into mitogen-activated protein kinase (MAPK) signalling through epidermal growth factor receptor (EGFR) transactivation". Thesis, McGill University, 2011. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=96903.
Повний текст джерелаLe récepteur F-prostanoïde (FP) est un récepteur de la famille des RCPG (récepteurs couplés aux protéines G), qui, une fois lié par son ligand naturel, la prostaglandine F2alpha (PGF2alpha), induit la production d'IP3, menant à l'activation de la protéine kinase C (PKC) suivie de l'activation des MAP kinases ERK1/2. Dans ce manuscrit, nous démontrons que l'AL-8810, étant reconnu comme un antagoniste de la production d'IP3 induite par le PGF2alpha, est capable d'activer la voie des ERK1/2 d'une manière indépendante à la PKC. En effet, nous démontrons que la PKCbeta1-GFP transloque à la membrane plasmique suite au traitement avec la PGF2alpha, alors que l'AL-8810 n'induit aucune translocation. Cependant, l'AL-8810, contrairement à la PGF2alpha, est capable d'induire la phosphorylation du récepteur à l'EGF (EGFR), menant à l'activation de ERK1/2. La phosphorylation de l'EGFR induite par l'AL-8810 est blocable par une antagoniste de l'EGFR, suggérant un mécanisme de transactivation de ce dernier. De plus, le batimastat, un inhibiteur non-spécifique des métalloprotéases matricielles (MMP) abolit l'induction des ERK1/2 par la PGF2alpha ainsi que par l'AL-8810, suggérant que la PGF2alpha signale probablement par un mécanisme indépendant de la transactivation de l'EGFR. Dans des cellules ostéoblastes, la PGF2alpha et l'AL-8810 activent ERK1/2 d'une manière dépendante au EGFR, même si la PKC demeure essentielle pour l'activation des voies en aval de la PGF2alpha, puisque l'interleukine-6 et la prolifération cellulaire (tous deux dépendants de la PKC) sont induits seulement par la PGF2alpha. En conclusion, nous montrons l'activation biaisée du FP par l'AL-8810 menant à l'activation de ERK1/2 via un mécanisme de transactivation par la voie EGFR-MMP. Ces résultats suggèrent aussi un nouveau mécanisme d'activation de ERK1/2 indépendant du EGFR et induit par la voie PKC-MMP.
Khalid, Saifudin. "Inhalational cough challenges in the assessment of cough." Thesis, University of Manchester, 2013. https://www.research.manchester.ac.uk/portal/en/theses/inhalational-cough-challenges-in-the-assessment-of-cough(8788e20e-3f76-4600-bdc1-e9bee31b5c01).html.
Повний текст джерелаКниги з теми "Prostaglandins Antagonists"
NATO Advanced Study Institute on Prostanoids and Drugs (1988 Erice, Italy). Prostanoids and drugs. New York: Plenum Press, 1989.
Знайти повний текст джерелаKarim, Sultan M. M. Practical Applications of Prostaglandins and their Synthesis Inhibitors. Springer, 2012.
Знайти повний текст джерелаMarc, Bygdeman, Berger Gary S, and Keith Louis G, eds. Prostaglandins and their inhibitors in clinical obstetrics and gynaecology. Lancaster: MTP Press, 1986.
Знайти повний текст джерелаBygdeman, Marc. Prostaglandins and their Inhibitors in Clinical Obstetrics and Gynaecology. Springer, 2012.
Знайти повний текст джерелаMarc, Bydgeman, Berger Gary S, and Keith Louis G, eds. Prostaglandins and their inhibitors in clinical obstetrics and gynaecology. Lancaster: MTP Press, 1986.
Знайти повний текст джерелаProstanoids and Drugs. Springer, 1990.
Знайти повний текст джерелаSamuelson, B. Prostanoids and Drugs. Springer, 2012.
Знайти повний текст джерелаSamuelson, B. Prostanoids and Drugs. Springer, 2012.
Знайти повний текст джерела1934-, Harris Jules E., Braun Donald P, and Anderson Kenning M, eds. Prostaglandin inhibitors in tumor immunology and immunotherapy. Boca Raton: CRC Press, 1994.
Знайти повний текст джерелаIversen, Leslie. Endocannabinoids. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780190846848.003.0004.
Повний текст джерелаЧастини книг з теми "Prostaglandins Antagonists"
Ford-Hutchinson, A. W. "Therapeutic Aspects of Leukotriene Antagonists and Inhibitors." In Prostaglandins, Leukotrienes, Lipoxins, and PAF, 431–37. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4899-0727-1_41.
Повний текст джерелаFord-Hutchinson, A. W. "Novel Leukotriene D4 Receptor Antagonists and 5-Lipoxygenase Inhibitors: Implications in Human Disease." In Prostaglandins and Leukotrienes in Gastrointestinal Diseases, 50–54. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-73316-1_11.
Повний текст джерелаRuppin, H. "Ulcer Healing Drugs and Endogenous Prostaglandins: Carbenoxolone, Antacids, Sucralfate, Bismuth, and H2-Receptor Antagonists." In Prostaglandins and Leukotrienes in Gastrointestinal Diseases, 213–22. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-73316-1_43.
Повний текст джерелаMest, H. J., T. Rein, A. Riedel, W. Köpernik, and C. Brequet. "Effect of BN 52256 and Other Mediator Antagonists on Ouabain-Induced Ventricular Fibrillation in Sensitized Guinea-Pigs and on Ischemia-Induced Fibrillation in Rats." In Prostaglandins in the Cardiovascular System, 228–34. Basel: Birkhäuser Basel, 1992. http://dx.doi.org/10.1007/978-3-0348-7262-1_32.
Повний текст джерелаFritsch, W. P. "Benefits and Risks of Long-term Medical Therapy with Histamine H2-receptor Antagonists in Ulcer Disease — A Physician’s View." In Prostaglandins and Leukotrienes in Gastrointestinal Diseases, 291–95. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-73316-1_58.
Повний текст джерелаSchumpelick, V., G. Arlt, and G. Winkeltau. "Benefits and Risks of Long-term Medical Therapy with Histamine H2-Receptor Antagonists in Ulcer Disease: A Surgeon’s View." In Prostaglandins and Leukotrienes in Gastrointestinal Diseases, 296–301. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-73316-1_59.
Повний текст джерелаPill, J., J. Metz, K. Stegmeier, and F. Hartig. "Effects of Daltroban, a Thromboxane (TX) A2 Receptor Antagonist, on Lipid Metabolism and Atherosclerosis." In Prostaglandins in the Cardiovascular System, 107–13. Basel: Birkhäuser Basel, 1992. http://dx.doi.org/10.1007/978-3-0348-7262-1_16.
Повний текст джерелаDarius, Harald, Jutta Michael-Hepp, and Jürgen Meyer. "Receptor Binding Properties of the New and Specific Thromboxane Receptor Antagonist Bay U 3405." In Prostaglandins in the Cardiovascular System, 157–61. Basel: Birkhäuser Basel, 1992. http://dx.doi.org/10.1007/978-3-0348-7262-1_21.
Повний текст джерелаPettipher, Roy, and Trevor T. Hansel. "Antagonists of the prostaglandin D2 receptor CRTH2." In New Drugs and Targets for Asthma and COPD, 193–98. Basel: KARGER, 2010. http://dx.doi.org/10.1159/000320819.
Повний текст джерелаBenetos, Athanassios, Haralambos Gavras, John M. Stewart, Raymond Vavrek, Simon Hatinoglou, and Irene Gavras. "The Antihypertensive Contribution of Bradykinin as Assessed by a Specific Bradykinin Antagonist." In Vasodepressor Hormones in Hypertension: Prostaglandins and Kallikrein-Kinins, 355–64. Basel: Birkhäuser Basel, 1987. http://dx.doi.org/10.1007/978-3-0348-9299-5_37.
Повний текст джерелаТези доповідей конференцій з теми "Prostaglandins Antagonists"
Van Nueten, J. M., W. J. Janssens, and F. De Clerck. "VASOCONSTRICTION IN RESPONSE TO HUMAN PLATELET-VESSEL WALL INTERACTIONS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644598.
Повний текст джерелаVan Diest, M. J., T. J. Verbeuren, and A. G. Herman. "RELAXATIONS INDUCED BY LIPOXYGENASE METABOLITES OF ARACHI-DONIC ACID IN SPLENIC ARTERIES OF THE DOG." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643796.
Повний текст джерелаHatmi, M., A. Del Maschio, J. Lefort, G. De Gaetano, B. B. Varqaftiq, and C. Cerletti. "EFFECTS OF SULFINPYRAZONE AND ITS METABOLITE G25671 ON PLATELET ACTIVATION AND DESENSITIZATION AND ON BRONCHOCONSTRICTION INDUCED BY THE PROSTAGLANDIN ENDOPEROXIDE ANALOGUE U46619." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643854.
Повний текст джерелаNonomura, Kazuhiko, Katsuyoshi Miyama, Kiyoshi Kanazawa, Takako Okumura, Yoshiyuki Okumura, Masanobu Oshima, Satoru Takahashi, and Yukinori Take. "Abstract 893: Anticancer effect and mechanism of prostaglandin E2 receptor EP4 antagonist." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-893.
Повний текст джерелаChen, Wentao, Rowie Borst, Jian Luo, Mohammad M. Chizari, Luisa Chocarro De Erauso, Veit J. Erpenbeck, Shamsah Kazani, David A. Sandham, and Luzheng Xue. "Fevipiprant antagonises prostaglandin D2-induced activation of type-2 CD8 T cells (Tc2)." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.oa4953.
Повний текст джерелаSzczeklik, A., R. J. Gryglewski, and M. Wandzilak. "THE EFFECT OF SIX PROSTAGLANDINS, PROSTACYCLIN AND ILOPROST ON GENERATION OF SUPEROXIDE ANIONS (0J) BY HUMAN NEUTROPHILS (PMNs) ACTIVATED BY ZYMOSAN OR FMLP." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643160.
Повний текст джерелаMa, Xinrong, Namita Kundu, Peter Collin, and Amy M. Fulton. "Abstract 609: Frondoside antagonizes the prostaglandin E receptor EP4 and inhibits breast tumor metastasis." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-609.
Повний текст джерелаShirakami, Yohei, Hiroyasu Sakai, Takahiro Kochi, Takayasu Ideta, Tsuneyuki Miyazaki, Masahito Shimizu, and Mitsuru Seishima. "Abstract 2805: Preventive effect of a prostaglandin E receptor EP4 antagonist RQ-00015986 on rat colon tumorigenesis." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2805.
Повний текст джерелаTaylor Meadows, K., S. Sahdeo, S. Murphy, G. J. Opiteck, H. Ortega, L. Carter, and L. Salter-Cid. "GB001 Is a Differentiated Potent Prostaglandin D2 Antagonist with Long Receptor Residence Time and Extended Pharmacodynamic Efficacy." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7417.
Повний текст джерелаOpiteck, Gregory, Kristen Taylor Meadows, Eric Butz, Scott Sugden, Richard Aranda, and Hector Ortega. "GB001, a selective prostaglandin D2 receptor 2 antagonist, blocks signaling in the peripheral blood of healthy subjects." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.1421.
Повний текст джерела